Jyoti Palaniappan - Jun 17, 2021 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)

Role
SVP, Diagnostics, T-Detect
Signature
/s/ Jyoti Palaniappan by Eric Billings as attorney-in-fact
Stock symbol
ADPT
Transactions as of
Jun 17, 2021
Transactions value $
-$33,802
Form type
4
Date filed
6/21/2021, 08:00 PM
Previous filing
May 19, 2021
Next filing
Jul 19, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADPT Common Stock Options Exercise $14.7K +651 +7.11% $22.55 9.81K Jun 17, 2021 Direct F1
transaction ADPT Common Stock Sale -$26K -651 -6.64% $40.00* 9.16K Jun 17, 2021 Direct F1
transaction ADPT Common Stock Options Exercise $29.3K +1.3K +14.21% $22.55 10.5K Jun 18, 2021 Direct F1
transaction ADPT Common Stock Sale -$51.8K -1.3K -12.44% $39.80* 9.16K Jun 18, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADPT Stock Option (Right to Buy) Options Exercise $0 -651 -0.61% $0.00 106K Jun 17, 2021 Common Stock 651 $22.55 Direct F1, F3
transaction ADPT Stock Option (Right to Buy) Options Exercise $0 -1.3K -1.22% $0.00 105K Jun 18, 2021 Common Stock 1.3K $22.55 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020.
F2 The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $39.59 to 40.00, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3 The options vested with respect to 1/4 of such shares on March 18, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.